摘要:
Processes for preparing prostacyclin analogs which are 9-deoxy-6,9-epoxymethano derivatives of prostaglandin F.sub.1.alpha. -type compounds, illustrated, for example, by a compound of the formula ##STR1## wherein .about. indicates alpha or beta configuration; including the products and intermediates produced therein, said products having pharmacological utility.
摘要:
Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.
摘要:
Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.
摘要:
Prostaglandin (PG.sub.1) derivatives having (1) a 6-keto feature, together with a 9-deoxy-9-hydroxymethyl feature for example ##STR1## or (2) a 9-deoxy-6,9-epoxymethano feature together with a 5-halo or 6-hydroxy feature, for example ##STR2## or a 5,6-didehydro feature, for example in an enol ether of the formula ##STR3## said derivatives having pharmacological activity. Processess for preparing them and the appropriate intermediates are disclosed.
摘要:
The present specification provides novel intermediates and novel processes for the synthesis of various side chain and skeletal analogs of Thromboxane B.sub.2 (11.beta.-homo-11a-oxa-PGF.sub.2.alpha.). These analogs are particularly and especially useful as reproductive cycle control agents.
摘要:
The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B.sub.2 11a-homo-11a-oxa-PGF.sub.2.alpha.), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in the above processes, and corresponding acyclic lactones.
摘要:
The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B.sub.2 11a-homo-11a-oxa-PGF.sub.2.alpha.), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in the above processes, and corresponding acyclic lactones.
摘要:
The present specification provides novel intermediates and novel processes for the synthesis of Thromboxane B.sub.2 11a-homo-11a-oxa-PGF.sub.2a), its 15-epimer, and various carboxyl derivatives thereof. In particular, there are disclosed various bicyclic tetrahydrofuran-containing lactones useful in the above processes, and corresponding acyclic lactones.
摘要:
Oxazolidines having the formula ##SPC1##Wherein .about. indicates endo or exo attachment, but differing in their stereoisomeric configuration, are prepared by reaction of the isomers of a tricyclic lactone aldehyde of the formula ##SPC2##Wherein .about. is as defined above, with d- or l-ephedrine; useful for separating optically active isomers of the aldehyde.
摘要:
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.